Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NASDAQ:FLGT NASDAQ:LFST NASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$54.60+2.9%$41.27$7.57▼$63.06$2.25B0.72868,082 shs806,685 shsFLGTFulgent Genetics$22.03+0.4%$20.42$14.57▼$23.56$671.56M0.82199,007 shs206,787 shsLFSTLifeStance Health Group$5.15-1.5%$4.84$3.74▼$8.61$2.03B1.171.95 million shs1.83 million shsVCYTVeracyte$31.83-1.4%$28.03$22.61▼$47.32$2.54B2.07903,230 shs745,371 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+2.88%-2.38%+5.88%+362.32%+264.49%FLGTFulgent Genetics+0.41%+1.15%+2.37%+8.52%-3.16%LFSTLifeStance Health Group-1.53%-0.39%-4.81%+4.46%-24.60%VCYTVeracyte-1.39%+3.28%+5.85%+18.68%-7.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$54.60+2.9%$41.27$7.57▼$63.06$2.25B0.72868,082 shs806,685 shsFLGTFulgent Genetics$22.03+0.4%$20.42$14.57▼$23.56$671.56M0.82199,007 shs206,787 shsLFSTLifeStance Health Group$5.15-1.5%$4.84$3.74▼$8.61$2.03B1.171.95 million shs1.83 million shsVCYTVeracyte$31.83-1.4%$28.03$22.61▼$47.32$2.54B2.07903,230 shs745,371 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+2.88%-2.38%+5.88%+362.32%+264.49%FLGTFulgent Genetics+0.41%+1.15%+2.37%+8.52%-3.16%LFSTLifeStance Health Group-1.53%-0.39%-4.81%+4.46%-24.60%VCYTVeracyte-1.39%+3.28%+5.85%+18.68%-7.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 3.00Buy$56.503.48% UpsideFLGTFulgent Genetics 2.67Moderate Buy$25.3314.99% UpsideLFSTLifeStance Health Group 2.86Moderate Buy$8.5065.05% UpsideVCYTVeracyte 2.70Moderate Buy$40.9028.50% UpsideCurrent Analyst Ratings BreakdownLatest FLGT, VCYT, CELC, and LFST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $66.008/15/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$74.00 ➝ $70.008/8/2025VCYTVeracyteMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetUnderweight$28.008/8/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.50 ➝ $9.008/5/2025FLGTFulgent GeneticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$20.00 ➝ $30.008/4/2025FLGTFulgent GeneticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$23.00 ➝ $21.007/28/2025CELCCelcuityLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$28.00 ➝ $60.007/28/2025CELCCelcuityHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $50.007/28/2025CELCCelcuityNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$29.007/25/2025LFSTLifeStance Health GroupBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.007/1/2025CELCCelcuityStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$3.11 per shareN/AFLGTFulgent Genetics$283.47M2.38N/AN/A$36.92 per share0.60LFSTLifeStance Health Group$1.25B1.60$0.04 per share131.89$3.78 per share1.36VCYTVeracyte$445.76M5.62$1.02 per share31.13$15.17 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$111.78M-$3.45N/AN/AN/AN/A-150.07%-64.67%11/13/2025 (Estimated)FLGTFulgent Genetics-$42.71M-$1.66N/AN/AN/A-16.83%-2.26%-2.10%11/14/2025 (Estimated)LFSTLifeStance Health Group-$57.44M-$0.05N/AN/AN/A-1.23%-1.11%-0.76%11/6/2025 (Estimated)VCYTVeracyte$24.14M$0.3396.4644.21N/A5.50%6.07%5.53%11/5/2025 (Estimated)Latest FLGT, VCYT, CELC, and LFST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CELCCelcuity-$0.90-$1.04-$0.14-$1.04N/AN/A8/7/2025Q2 2025LFSTLifeStance Health Group-$0.03-$0.01+$0.02-$0.01$345.05 million$345.31 million8/1/2025Q2 2025FLGTFulgent Genetics-$0.23$0.07+$0.30-$0.62$76.21 million$81.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity2.244.584.58FLGTFulgent GeneticsN/A6.016.01LFSTLifeStance Health Group0.191.481.48VCYTVeracyteN/A5.435.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%FLGTFulgent Genetics48.06%LFSTLifeStance Health Group85.50%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipCELCCelcuity15.77%FLGTFulgent Genetics31.76%LFSTLifeStance Health Group3.20%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4042.43 million35.74 millionOptionableFLGTFulgent Genetics1,31330.61 million20.89 millionOptionableLFSTLifeStance Health Group10,218388.94 million376.49 millionOptionableVCYTVeracyte79078.67 million77.57 millionOptionableFLGT, VCYT, CELC, and LFST HeadlinesRecent News About These CompaniesAQR Capital Management LLC Lowers Stock Position in Veracyte, Inc. $VCYTSeptember 15 at 3:12 AM | marketbeat.comVeracyte, Inc. $VCYT Stake Trimmed by Great Lakes Advisors LLCSeptember 13, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) CEO Sells 7,667 SharesSeptember 10, 2025 | marketbeat.comVeracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual MeetingSeptember 10, 2025 | finance.yahoo.comVeracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 9, 2025 | seekingalpha.comMarc Stapley Sells 7,667 Shares of Veracyte (NASDAQ:VCYT) StockSeptember 9, 2025 | insidertrades.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Average Target Price from AnalystsSeptember 9, 2025 | americanbankingnews.comVeracyte, Inc. $VCYT Stake Lifted by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comBridgeway Capital Management LLC Sells 41,300 Shares of Veracyte, Inc. $VCYTSeptember 8, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 8, 2025 | marketbeat.comRaymond James Financial Inc. Purchases 172,010 Shares of Veracyte, Inc. $VCYTSeptember 6, 2025 | marketbeat.comPDT Partners LLC Sells 27,566 Shares of Veracyte, Inc. $VCYTSeptember 5, 2025 | marketbeat.comMagnetar Financial LLC Invests $651,000 in Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comTrexquant Investment LP Sells 10,790 Shares of Veracyte, Inc. $VCYTSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys 10,618 Shares of Veracyte, Inc. $VCYTSeptember 2, 2025 | marketbeat.comRafferty Asset Management LLC Has $3.29 Million Stock Position in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comNorthern Trust Corp Trims Stake in Veracyte, Inc. $VCYTSeptember 1, 2025 | marketbeat.comDriehaus Capital Management LLC Purchases 167,604 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 28,644 Shares of Veracyte, Inc. $VCYTAugust 31, 2025 | marketbeat.comNext Century Growth Investors LLC Lowers Stake in Veracyte, Inc. $VCYTAugust 30, 2025 | marketbeat.comVeracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare ConferenceAugust 29, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFLGT, VCYT, CELC, and LFST Company DescriptionsCelcuity NASDAQ:CELC$54.60 +1.53 (+2.88%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$55.63 +1.03 (+1.89%) As of 09/17/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Fulgent Genetics NASDAQ:FLGT$22.03 +0.09 (+0.41%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$21.90 -0.13 (-0.59%) As of 09/17/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.LifeStance Health Group NASDAQ:LFST$5.15 -0.08 (-1.53%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$5.16 +0.01 (+0.29%) As of 09/17/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Veracyte NASDAQ:VCYT$31.83 -0.45 (-1.39%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$31.84 +0.01 (+0.02%) As of 09/17/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Why CoreWeave's NVIDIA Deal Creates a Deep Moat for AI Investors Dave & Buster’s Stock: Is Now the Time to Make a PLAY? Resideo Technologies: Institutional Activity Signals 30% Upside This Stock Quietly Benefits From Oracle and NVIDIA’s AI Surge Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
